Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (“AKI”) and GEM-CKD as a treatment for chronic kidney disease (“CKD”).
Phase 2 · ActiveModality: Formulation of PHAD (TLR4 agonist)
Aliases Gemini
Target TLR4
Partnerships Vanderbilt University (licensed patent directed to methods of using PHAD for treating or preventing infections)
Indications
Acute kidney injury (AKI)(Phase 2)
Catalysts
— 2026
Status note Single Phase 2/3 adaptive design study agreed with FDA at end of 2025. During 2026 the company plans to build infrastructure (scientific advisory board, CRO engagement, blinded drug/placebo manufacture) to start the study as soon as feasible.
GEM-CKD
Preclinical · ActiveModality: Formulation of PHAD (TLR4 agonist)
Aliases Gemini
Target TLR4
Indications
Chronic kidney disease (CKD)(Preclinical)
Catalysts
— 2026
Status note Chronic (long-term) treatment for CKD. During 2026 the company intends to conduct preclinical toxicology studies to support a repeat-dose Phase 2 study.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.